Physician profile
Anu Garg
NPI 1548500259
$680.60
in general payments reported to CMS, 2019-2025
15 companies · $85.62 in 2025
The $85.62 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.56 · 2021: $16.76 · 2022: $132 · 2023: $46.00 · 2024: $383 · 2025: $85.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $102.15 | 2024 | Invega Sustenna, Invega Trinza |
| Merck Sharp & Dohme LLC | $92.22 | 2021-2024 | Gardasil, Gardasil 9, Vaxneuvance |
| Cranial Technologies, INC | $67.57 | 2022-2024 | Doc Band |
| Shield Therapeutics INC | $64.92 | 2023-2024 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $63.74 | 2024-2025 | Uzedy |
| Sage Therapeutics, LLC | $63.48 | 2024-2025 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $44.02 | 2024 | Abilify Asimtufii, Rexulti |
| Hologic Sales and Service, LLC | $28.12 | 2024 | Aptima, Thinprep 2000 Processor |
| Phadia US INC. | $24.75 | 2022 | |
| Novo Nordisk INC | $24.17 | 2025 | Wegovy |
| Biogen, INC. | $23.52 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $22.21 | 2024 | Slynd |
| Sanofi Pasteur INC. | $21.64 | 2024 | |
| Sobi, INC | $20.53 | 2022 | |
| Glaxosmithkline, LLC. | $17.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.